Treatment of sporotrichosis with itraconazole
dc.contributor.author | Sharkey-Mathis, Patricia Kay | en_US |
dc.contributor.author | Kauffman, Carol A. | en_US |
dc.contributor.author | Graybill, John R. | en_US |
dc.contributor.author | Stevens, David A. | en_US |
dc.contributor.author | Hostetler, John S. | en_US |
dc.contributor.author | Cloud, Gretchen A. | en_US |
dc.contributor.author | Dismukes, William E. | en_US |
dc.date.accessioned | 2006-04-10T15:57:39Z | |
dc.date.available | 2006-04-10T15:57:39Z | |
dc.date.issued | 1993-09 | en_US |
dc.identifier.citation | Sharkey-Mathis, Patricia Kay, Kauffman, Carol A., Graybill, John R., Stevens, David A., Hostetler, Johns., Cloud, Gretchen, Dismukes, William E. (1993/09)."Treatment of sporotrichosis with itraconazole." The American Journal of Medicine 95(3): 279-285. <http://hdl.handle.net/2027.42/31069> | en_US |
dc.identifier.uri | http://www.sciencedirect.com/science/article/B6TDC-4CM9413-1W/2/9508aee9e1bc6bdc00a74b768531d73a | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/31069 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8396321&dopt=citation | en_US |
dc.description.abstract | To describe the clinical presentation and outcomes of treatment with itraconazole in patients with sporotrichosis. A culture for Sporothrix schenckii or compatible histopathology was required for inclusion in the study. Patients with both cutaneous and systemic sporotrichosis were treated. Patients received from 100 to 600 mg of itraconazole daily for 3 to 18 months. Patients were classified as responders or nonresponders. Responders were further classified as remaining on treatment, relapsed, or free of disease. Nonresponders included patients who failed to respond or progressed during treatment with itraconazole. Twenty-seven patients (mean age: 53 years) were treated with 30 courses of itraconazole. Diabetes mellitus and alcoholism were present in eight and seven patients, respectively. Sites of involvement included lymphocutaneous alone in 9 patients, articular/osseous in 15 (multifocal in 3), and lung in 3. Prior therapy was unsuccessful in 11 patients. Among the 30 courses, there were 25 responders and 5 nonresponders. All 5 nonresponders received at least 200 mg daily of itraconazole for durations that ranged from 6 to 18 months. Of the 25 responders, 7 relapsed 1 to 7 months after treatment durations of 6 to 18 months. Of the 7 who relapsed, 2 are responding to a second course. One responder was lost to follow-up after 10 months of treatment with itraconazole. Of the remaining 17 responders, 3 remain on treatment, and 14 are free of disease over follow-up durations of 6 to 42 months (mean: 17.6 months). Itraconazole was well tolerated with few side effects noted. These results document the efficacy of itraconazole in the treatment of cutaneous and systemic sporotrichosis. | en_US |
dc.format.extent | 973544 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | en_US |
dc.title | Treatment of sporotrichosis with itraconazole | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Family Medicine and Primary Care | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Veterans Affairs Medical Center and University of Michigan Medical School, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Audie L. Murphy Memorial Veterans Hospital and University of Texas Health Science Center, San Antonio, Texas, USA | en_US |
dc.contributor.affiliationother | Audie L. Murphy Memorial Veterans Hospital and University of Texas Health Science Center, San Antonio, Texas, USA | en_US |
dc.contributor.affiliationother | Santa Clara Valley Medical Center and Stanford University Medical School, San Jose, California, USA | en_US |
dc.contributor.affiliationother | Santa Clara Valley Medical Center and Stanford University Medical School, San Jose, California, USA | en_US |
dc.contributor.affiliationother | University of Alabama at Birmingham, Birmingham, Alabama, USA | en_US |
dc.contributor.affiliationother | University of Alabama at Birmingham, Birmingham, Alabama, USA; National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA. | en_US |
dc.identifier.pmid | 8396321 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/31069/1/0000746.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1016/0002-9343(93)90280-3 | en_US |
dc.identifier.source | The American Journal of Medicine | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.